Menlo | Jotup

Menlo Therapeutics Appoints Andrew Saik as Chief Financial Officer

Retrieved on:

Tuesday, March 24, 2020

BRIDGEWATER, N.J., March 24, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (Menlo or the Company), a biopharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, appointed Andrew Saik as Chief Financial Officer and Treasurer, effective March 23, 2020.

Key Points:

BRIDGEWATER, N.J., March 24, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (Menlo or the Company), a biopharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, appointed Andrew Saik as Chief Financial Officer and Treasurer, effective March 23, 2020.
Andrew is an accomplished CFO and brings a wealth of experience to the senior management team at Menlo, said David Domzalski, Chief Executive Officer of Menlo Therapeutics.
Mr. Saik said Menlo is positioned to be a market leader in therapeutic dermatology, and I am thrilled to be joining at this exciting time.
Ilan Hadar, Menlos current Chief Financial Officer and Treasurer, will remain through a transition period in establishing U.S. financial operations.

Menlo Therapeutics Provides a Business Update in the Context of COVID-19

Retrieved on:

Friday, March 20, 2020

Menlo

BRIDGEWATER, N.J., March 20, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (Menlo or the Company), a biopharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today provided a business update in the context of the developing situation with the COVID-19 (coronavirus) pandemic.

Key Points:

BRIDGEWATER, N.J., March 20, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (Menlo or the Company), a biopharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today provided a business update in the context of the developing situation with the COVID-19 (coronavirus) pandemic.
At this time, Menlo does not anticipate any changes to key clinical and regulatory milestones in 2020, but is continuing to monitor the situation.
All patient visits have been conducted and the Company is now focusing on preparations for analyzing the data.
Menlo is committed to protecting and supporting the safety of our employees, patients, healthcare provider customers and their families, said David Domzalski, CEO of Menlo Therapeutics.

Menlo-Atherton High School Installs Shaw Sports Turf On Bettencourt Field

Retrieved on:

Wednesday, February 19, 2020

Menlo-Atherton High School, Menlo, Artificial turf, Geography of California, Menlo Park, California

"We replaced our old infield turf with new turf and added some square footage outside the dugouts and around home plate," said Paul Snow, Athletic Director at Menlo-Atherton High School.

Key Points:

"We replaced our old infield turf with new turf and added some square footage outside the dugouts and around home plate," said Paul Snow, Athletic Director at Menlo-Atherton High School.
Bettencourt Field has been the home field for the Menlo-Atherton baseball teams for over 15 years.
In need of repair and renovation, the school decided to install Shaw Sports Turf's TruHop synthetic turf specifically designed for baseball fields.
"I'm ecstatic Shaw Sports Turf could be involved with the Sequoia Unified School District and Menlo Atherton High School.

Foamix and Menlo Announce Shareholder Approval of Proposed Merger

Retrieved on:

Thursday, February 6, 2020

Companies, Economy of the United States, Airlines, SEC filings, U.S. Securities and Exchange Commission, Menlo, Proxy statement, Prospectus, US Airways, General Electric, Registration statement

Pending the expiration of a 30-day waiting period required by Israeli law and satisfaction of closing conditions set forth in the merger agreement between Foamix, Menlo and Giants Merger Subsidiary Ltd., a wholly-owned subsidiary of Menlo, Menlos merger subsidiary will merge with and into Foamix, with Foamix surviving as a wholly-owned subsidiary of Menlo.

Key Points:

Pending the expiration of a 30-day waiting period required by Israeli law and satisfaction of closing conditions set forth in the merger agreement between Foamix, Menlo and Giants Merger Subsidiary Ltd., a wholly-owned subsidiary of Menlo, Menlos merger subsidiary will merge with and into Foamix, with Foamix surviving as a wholly-owned subsidiary of Menlo.
On January 6, 2020, Menlo filed a Registration Statement on Form S-4 containing a joint proxy statement/prospectus of Menlo and Foamix and other documents concerning the proposed merger with the Securities and Exchange Commission (the SEC).
Foamix and Menlo may also file other relevant documents with the SEC regarding the proposed merger.
MENLOS AND FOAMIXS RESPECTIVE STOCKHOLDERS ARE URGED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS IN ITS ENTIRETY AND ANY OTHER DOCUMENTS FILED BY EACH OF MENLO AND FOAMIX WITH THE SEC IN CONNECTION WITH THE PROPOSED MERGER OR INCORPORATED BY REFERENCE THEREIN BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED MERGER AND THE PARTIES TO THE PROPOSED MERGER.

Foamix and Menlo Announce Shareholder Approval of Proposed Merger

Retrieved on:

Thursday, February 6, 2020

Companies, Economy of the United States, Airlines, SEC filings, U.S. Securities and Exchange Commission, Menlo, Proxy statement, Prospectus, US Airways, General Electric, Registration statement

Pending the expiration of a 30-day waiting period required by Israeli law and satisfaction of closing conditions set forth in the merger agreement between Foamix, Menlo and Giants Merger Subsidiary Ltd., a wholly-owned subsidiary of Menlo, Menlos merger subsidiary will merge with and into Foamix, with Foamix surviving as a wholly-owned subsidiary of Menlo.

Key Points:

Pending the expiration of a 30-day waiting period required by Israeli law and satisfaction of closing conditions set forth in the merger agreement between Foamix, Menlo and Giants Merger Subsidiary Ltd., a wholly-owned subsidiary of Menlo, Menlos merger subsidiary will merge with and into Foamix, with Foamix surviving as a wholly-owned subsidiary of Menlo.
On January 6, 2020, Menlo filed a Registration Statement on Form S-4 containing a joint proxy statement/prospectus of Menlo and Foamix and other documents concerning the proposed merger with the Securities and Exchange Commission (the SEC).
Foamix and Menlo may also file other relevant documents with the SEC regarding the proposed merger.
MENLOS AND FOAMIXS RESPECTIVE STOCKHOLDERS ARE URGED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS IN ITS ENTIRETY AND ANY OTHER DOCUMENTS FILED BY EACH OF MENLO AND FOAMIX WITH THE SEC IN CONNECTION WITH THE PROPOSED MERGER OR INCORPORATED BY REFERENCE THEREIN BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED MERGER AND THE PARTIES TO THE PROPOSED MERGER.

Foamix Announces OrbiMed’s Support of Merger with Menlo Therapeutics

Retrieved on:

Friday, January 17, 2020

Menlo, Mergers and acquisitions

We are delighted to have the support of both OrbiMed and Perceptive Advisors for our transformative transaction with Menlo Therapeutics, said David Domzalski, Chief Executive Officer of Foamix.

Key Points:

We are delighted to have the support of both OrbiMed and Perceptive Advisors for our transformative transaction with Menlo Therapeutics, said David Domzalski, Chief Executive Officer of Foamix.
Foamix uses its website as a channel to distribute information about Foamix and its product candidates from time to time.
Foamix and Menlo may also file other relevant documents with the SEC regarding the proposed merger.
Readers should also carefully review the risk factors described in other documents that Menlo and Foamix file from time to time with the SEC.

OrbiMed Supports the Proposed Foamix Pharmaceuticals Ltd. And Menlo Therapeutics Inc. Merger

Retrieved on:

Thursday, January 16, 2020

Finance, Banking, Health, Professional services, Pharmaceutical, Companies, Corporate finance, Business, Fairfield, Connecticut, General Electric, RCA, Schenectady, New York, Thomas Edison, Menlo, Mergers and acquisitions, Proxy, Economy

OrbiMed Advisors LLC (OrbiMed), on behalf of its clients, has evaluated the Joint Proxy Statement/Prospectus for the proposed merger of Foamix Pharmaceuticals Ltd. (Foamix) and Menlo Therapeutics Inc. (Menlo).

Key Points:

OrbiMed Advisors LLC (OrbiMed), on behalf of its clients, has evaluated the Joint Proxy Statement/Prospectus for the proposed merger of Foamix Pharmaceuticals Ltd. (Foamix) and Menlo Therapeutics Inc. (Menlo).
After careful consideration and review of the Form S-4/A Registration Statement filed by Menlo on January 6, 2020, OrbiMed believes that the proposed merger of Foamix and Menlo is a compelling transaction with the potential to significantly enhance value for Foamix shareholders.
Accordingly, OrbiMed intends to vote in favor of the approval and adoption of the Merger Agreement in its entirety.
OrbiMed clients and Foamix have also entered into a Credit Agreement for term loans totaling $25 million.

Silver Lake To Acquire First Advantage

Retrieved on:

Monday, November 25, 2019

Law firms, Simpson Thacher & Bartlett, Silver Lake, Thacher, Stifel, Menlo

ATLANTA and MENLO PARK, Calif., Nov. 25, 2019 /PRNewswire/ -- First Advantage , a global technology and information services leader in background check and drug screening solutions, and Silver Lake, a global leader in technology investing, today announced that Silver Lake has signed a definitive agreement to acquire First Advantage from Symphony Technology Group (STG).

Key Points:

ATLANTA and MENLO PARK, Calif., Nov. 25, 2019 /PRNewswire/ -- First Advantage , a global technology and information services leader in background check and drug screening solutions, and Silver Lake, a global leader in technology investing, today announced that Silver Lake has signed a definitive agreement to acquire First Advantage from Symphony Technology Group (STG).
"As employers compete for talent, they seek best-in-class technology partners like First Advantage to provide timely and trusted intelligence to support hiring, risk management, and brand protection," said Joe Osnoss, Managing Director of Silver Lake.
In partnership with Silver Lake, the company is well positioned to continue to deliver innovative solutions to its 35,000 clients around the world."
Stifel acted as financial advisor and Simpson Thacher & Bartlett LLP served as legal counsel to Silver Lake.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Merger of Menlo Therapeutics Inc. with Foamix Pharmaceuticals Ltd. is Fair to MNLO Shareholders

Retrieved on:

Wednesday, November 13, 2019

Corporate finance, Finance, Economy, Money, Equity securities, Menlo, Stock, Mergers and acquisitions, Common stock

You are hereby notifiedthat Levi & Korsinsky, LLP has commenced aninvestigationinto thefairness of the merger of Menlo with Foamix Pharmaceuticals Ltd. (Foamix) (NASDAQ: FOMX).

Key Points:

You are hereby notifiedthat Levi & Korsinsky, LLP has commenced aninvestigationinto thefairness of the merger of Menlo with Foamix Pharmaceuticals Ltd. (Foamix) (NASDAQ: FOMX).
Under the terms of the transaction, each share of Foamix stock will be exchanged for 0.5924 of a share of Menlo common stock and a contingent stock right.
Following the merger, Foamix shareholders will own approximately 59% of the combined company and Menlo shareholders will own approximately 41%.
The Menlo merger investigation concerns whether the Board of Menlo breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction and whether the merger with Foamix undervalues Menlo shares, thus unlawfully harming Menlo shareholders.

Menlo Therapeutics Reports Third Quarter 2019 Financial Results and Provides Program Updates

Retrieved on:

Thursday, October 31, 2019

Menlo, Forward-looking statement

Menlo expects to report top-line data from these PN Phase 3 trials in March or April of 2020.

Key Points:

Menlo expects to report top-line data from these PN Phase 3 trials in March or April of 2020.
Menlo is currently enrolling patients in a 52-week, multicenter, open-label safety study of serlopitant for the treatment of pruritus.
Menlo reported a net loss of $16.9 million for the third quarter of 2019, compared to a net loss of $12.8 million for the same period in 2018.
Such forward-looking statements involve substantial risk and uncertainties that could cause Menlo Therapeutics development program for serlopitant, future financial results, achievements or performance to differ significantly from those expressed or implied by the forward-looking statements.